Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

Gray, Heidi J; Bell-McGuinn, Katherine; Fleming, Gini F; Cristea, Mihaela; Xiong, Hao; Sullivan, Danielle; Luo, Yan; McKee, Mark D; Munasinghe, Wijith; Martin, Lainie P

Gray, Heidi J; Bell-McGuinn, Katherine; Fleming, Gini F; Cristea, Mihaela; Xiong, Hao; Sullivan, Danielle; Luo, Yan; McKee, Mark D; Munasinghe, Wijith; Martin, Lainie P.

Affiliation

Gray HJ; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: hgray@uw.edu.
Bell-McGuinn K; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: katherinebellmcguinn@outlook.com.
Fleming GF; The University of Chicago Medicine, Chicago, IL, USA. Electronic address: gfleming@medicine.bsd.uchicago.edu.
Cristea M; City of Hope National Medical Center, Duarte, CA, USA. Electronic address: MCristea@coh.org.
Xiong H; AbbVie Inc., North Chicago, IL, USA. Electronic address: Hao.Xiong@AbbVie.com.
Sullivan D; AbbVie Inc., North Chicago, IL, USA. Electronic address: danielle.sullivan@abbvie.com.
Luo Y; AbbVie Inc., North Chicago, IL, USA. Electronic address: yan.luo@abbvie.com.
McKee MD; AbbVie Inc., North Chicago, IL, USA. Electronic address: mark.mckee@AbbVie.com.
Munasinghe W; AbbVie Inc., North Chicago, IL, USA. Electronic address: wijith.munasinghe@abbvie.com.
Martin LP; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: lainie.martin@fccc.edu.

Gynecol Oncol ; 148(3): 507-514, 2018 03.

Article in En | MEDLINE | ID: mdl-29352572

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Ovarian Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Anemia/chemically induced; Area Under Curve; Bayes Theorem; Benzimidazoles/administration & dosage; Bile Duct Neoplasms/drug therapy; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Carboplatin/administration & dosage; Carcinoma, Basal Cell/drug therapy; Carcinoma, Hepatocellular/drug therapy; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Squamous Cell/drug therapy; Carcinoma, Transitional Cell/drug therapy; Cholangiocarcinoma/drug therapy; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Female; Gallbladder Neoplasms/drug therapy; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms/drug therapy; Kidney Pelvis; Liver Neoplasms/drug therapy; Lung Neoplasms/drug therapy; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma/drug therapy; Middle Aged; Nausea/chemically induced; Neoplasm Metastasis; Neutropenia/chemically induced; Ovarian Neoplasms/genetics; Ovarian Neoplasms/pathology; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage; Prostatic Neoplasms/drug therapy; Skin Neoplasms/drug therapy; Thrombocytopenia/chemically induced; Treatment Outcome; Gemcitabine

Key words

BRCA1/2 mutations; Ovarian cancer; PARP inhibitor; Phase I; Veliparib

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Prognostic_studies Limits: Aged80 Language: En Journal: Gynecol Oncol Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google